Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 18Cr 0 16Cr 15Cr 14Cr 26Cr 1.7TCr 26Cr 175.25Cr 68Cr 839.5Cr 68Cr 66Cr 2.92TCr | P/E 2026 * |
11.5x | P/E 2027 * | 44.8x |
|---|---|---|---|---|---|
| Enterprise Value | 18Cr 0 16Cr 15Cr 14Cr 26Cr 1.7TCr 26Cr 175.25Cr 68Cr 839.5Cr 68Cr 66Cr 2.92TCr | EV / Sales 2026 * |
2.31x | EV / Sales 2027 * | 2.67x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 58 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 58 | 24/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 82 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 58 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 18Cr | |
| +0.68% | +1.59% | +40.86% | +146.49% | 1LCr | |
| +1.70% | +7.13% | +60.67% | +49.53% | 58TCr | |
| +3.76% | +12.48% | +31.34% | +80.44% | 42TCr | |
| +5.66% | -2.44% | +22.01% | +15.66% | 33TCr | |
| +1.34% | +6.74% | +32.63% | +41.70% | 28TCr | |
| +1.09% | +6.90% | +37.22% | +24.53% | 28TCr | |
| +1.32% | +12.69% | -27.48% | -41.27% | 21TCr | |
| +1.32% | +5.27% | +26.76% | +58.14% | 19TCr | |
| -0.62% | +0.26% | +17.14% | +62.08% | 16TCr | |
| Average | +1.49% | +2.68% | +26.80% | +48.59% | 38.19TCr | |
| Weighted average by Cap. | +1.77% | +2.18% | +34.27% | +70.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.83Cr 0 6.88Cr 6.34Cr 5.92Cr 11Cr 738.82Cr 11Cr 76Cr 29Cr 364.2Cr 29Cr 29Cr 1.27TCr | 6.76Cr 0 5.93Cr 5.47Cr 5.11Cr 9.59Cr 637.54Cr 9.77Cr 66Cr 25Cr 314.27Cr 25Cr 25Cr 1.09TCr |
| Net income | 1.57Cr 0 1.38Cr 1.27Cr 1.19Cr 2.23Cr 148.36Cr 2.27Cr 15Cr 5.91Cr 73Cr 5.9Cr 5.77Cr 254.15Cr | 40.74L 0 35.78L 32.97L 30.82L 57.81L 38Cr 58.87L 3.96Cr 1.53Cr 19Cr 1.53Cr 1.5Cr 66Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
